Literature DB >> 25712342

FOXP3 Controls an miR-146/NF-κB Negative Feedback Loop That Inhibits Apoptosis in Breast Cancer Cells.

Runhua Liu1, Cong Liu2, Dongquan Chen3, Wei-Hsiung Yang4, Xiuping Liu5, Chang-Gong Liu5, Courtney M Dugas6, Fei Tang7, Pan Zheng7, Yang Liu7, Lizhong Wang1.   

Abstract

FOXP3 functions not only as the master regulator in regulatory T cells, but also as an X-linked tumor suppressor. The tumor-suppressive activity of FOXP3 has been observed in tumor initiation, but its role during tumor progression remains controversial. Moreover, the mechanism of FOXP3-mediated tumor-suppressive activity remains largely unknown. Using chromatin immunoprecipitation (ChIP) sequencing, we identified a series of potential FOXP3-targeted miRNAs in MCF7 cells. Notably, FOXP3 significantly induced the expression of miR-146a/b. In vitro, FOXP3-induced miR-146a/b prevented tumor cell proliferation and enhanced apoptosis. Functional analyses in vitro and in vivo revealed that FOXP3-induced miR-146a/b negatively regulates NF-κB activation by inhibiting the expression of IRAK1 and TRAF6. In ChIP assays, FOXP3 directly bound the promoter region of miR-146a but not of miR-146b, and FOXP3 interacted directly with NF-κB p65 to regulate an miR-146-NF-κB negative feedback regulation loop in normal breast epithelial and tumor cells, as demonstrated with luciferase reporter assays. Although FOXP3 significantly inhibited breast tumor growth and migration in vitro and metastasis in vivo, FOXP3-induced miR-146a/b contributed only to the inhibition of breast tumor growth. These data suggest that miR-146a/b contributes to FOXP3-mediated tumor suppression during tumor growth by triggering apoptosis. The identification of a FOXP3-miR-146-NF-κB axis provides an underlying mechanism for disruption of miR-146 family member expression and constitutive NF-κB activation in breast cancer cells. Linking the tumor suppressor function of FOXP3 to NF-κB activation reveals a potential therapeutic approach for cancers with FOXP3 defects. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25712342      PMCID: PMC4706751          DOI: 10.1158/0008-5472.CAN-14-2108

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  47 in total

1.  NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses.

Authors:  Konstantin D Taganov; Mark P Boldin; Kuang-Jung Chang; David Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-02       Impact factor: 11.205

2.  Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells.

Authors:  Ye Zheng; Steven Z Josefowicz; Arnold Kas; Tin-Tin Chu; Marc A Gavin; Alexander Y Rudensky
Journal:  Nature       Date:  2007-01-21       Impact factor: 49.962

3.  MicroRNA-146a targets PRKCE to modulate papillary thyroid tumor development.

Authors:  Xiaoping Zhang; Dan Li; Maoquan Li; Meng Ye; Lanbao Ding; Haidong Cai; Da Fu; Zhongwei Lv
Journal:  Int J Cancer       Date:  2013-09-18       Impact factor: 7.396

4.  The function of multiple IkappaB : NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis.

Authors:  Qiang G Dong; Guido M Sclabas; Shuichi Fujioka; Christian Schmidt; Bailu Peng; TianAi Wu; Ming-Sound Tsao; Douglas B Evans; James L Abbruzzese; Timothy J McDonnell; Paul J Chiao
Journal:  Oncogene       Date:  2002-09-19       Impact factor: 9.867

5.  FOXP3 is a novel transcriptional repressor for the breast cancer oncogene SKP2.

Authors:  Tao Zuo; Runhua Liu; Huiming Zhang; Xing Chang; Yan Liu; Lizhong Wang; Pan Zheng; Yang Liu
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

6.  Breast cancer metastasis: demonstration that FOXP3 regulates CXCR4 expression and the response to CXCL12.

Authors:  Stephen Douglass; Annette P Meeson; Dorota Overbeck-Zubrzycka; John G Brain; Miriam R Bennett; Christopher A Lamb; Thomas W J Lennard; David Browell; Simi Ali; John A Kirby
Journal:  J Pathol       Date:  2014-07-09       Impact factor: 7.996

7.  TNFα induced FOXP3-NFκB interaction dampens the tumor suppressor role of FOXP3 in gastric cancer cells.

Authors:  Qiang Hao; Weina Li; Cun Zhang; Xin Qin; Xiaochang Xue; Meng Li; Zhen Shu; Tianjiao Xu; Yujin Xu; Weihua Wang; Wei Zhang; Yingqi Zhang
Journal:  Biochem Biophys Res Commun       Date:  2012-11-22       Impact factor: 3.575

8.  FOXP3 inhibits NF-κB activity and hence COX2 expression in gastric cancer cells.

Authors:  Qiang Hao; Cun Zhang; Yuan Gao; Shuning Wang; Jialin Li; Meng Li; Xiaochang Xue; Weina Li; Wei Zhang; Yingqi Zhang
Journal:  Cell Signal       Date:  2013-12-02       Impact factor: 4.315

9.  Phosphorylation of FOXP3 by LCK downregulates MMP9 expression and represses cell invasion.

Authors:  Kumiko Nakahira; Akihiro Morita; Nam-Soon Kim; Itaru Yanagihara
Journal:  PLoS One       Date:  2013-10-14       Impact factor: 3.240

10.  Features of mammalian microRNA promoters emerge from polymerase II chromatin immunoprecipitation data.

Authors:  David L Corcoran; Kusum V Pandit; Ben Gordon; Arindam Bhattacharjee; Naftali Kaminski; Panayiotis V Benos
Journal:  PLoS One       Date:  2009-04-23       Impact factor: 3.240

View more
  62 in total

1.  Silencing of CD24 Enhances the PRIMA-1-Induced Restoration of Mutant p53 in Prostate Cancer Cells.

Authors:  Wei Zhang; Bin Yi; Chao Wang; Dongquan Chen; Sejong Bae; Shi Wei; Rong-Jun Guo; Changming Lu; Lisa L H Nguyen; Wei-Hsiung Yang; James W Lillard; Xingyi Zhang; Lizhong Wang; Runhua Liu
Journal:  Clin Cancer Res       Date:  2015-12-28       Impact factor: 12.531

2.  miR-146b-5p promotes VSMC proliferation and migration.

Authors:  Hairong Wang; Mei Jiang; Zhenxing Xu; Hui Huang; Peihua Gong; Hua Zhu; Changwu Ruan
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

3.  miR-146b antagomir-treated human Tregs acquire increased GVHD inhibitory potency.

Authors:  Yunjie Lu; Keli L Hippen; Amanda L Lemire; Jian Gu; Weizhi Wang; Xuhao Ni; Parvathi Ranganathan; Bruce L Levine; James L Riley; Carl H June; Laurence A Turka; David H Munn; Ramiro Garzon; Ling Lu; Bruce R Blazar
Journal:  Blood       Date:  2016-08-02       Impact factor: 22.113

Review 4.  MiR-146a/b: a family with shared seeds and different roots.

Authors:  Mark R Paterson; Alison J Kriegel
Journal:  Physiol Genomics       Date:  2017-02-17       Impact factor: 3.107

5.  Edwardsiella tarda-induced miRNAs in a teleost host: Global profile and role in bacterial infection as revealed by integrative miRNA-mRNA analysis.

Authors:  Yong-Hua Hu; Bao-Cun Zhang; Hai-Zhen Zhou; Xiao-Lu Guan; Li Sun
Journal:  Virulence       Date:  2017-08-01       Impact factor: 5.882

6.  Snail-Modulated MicroRNA 493 Forms a Negative Feedback Loop with the Insulin-Like Growth Factor 1 Receptor Pathway and Blocks Tumorigenesis.

Authors:  Arathy S Kumar; Sankar Jagadeeshan; Ravi Shankar Pitani; Vijayalakshmi Ramshankar; Kesavan Venkitasamy; Ganesh Venkatraman; Suresh K Rayala
Journal:  Mol Cell Biol       Date:  2017-03-01       Impact factor: 4.272

Review 7.  Sexual dimorphism in cancer.

Authors:  Andrea Clocchiatti; Elisa Cora; Yosra Zhang; G Paolo Dotto
Journal:  Nat Rev Cancer       Date:  2016-04-15       Impact factor: 60.716

Review 8.  Clinico-Pathological Importance of miR-146a in Lung Cancer.

Authors:  Javaid Ahmad Wani; Sabhiya Majid; Andleeb Khan; Azher Arafah; Ajaz Ahmad; Basit Latief Jan; Naveed Nazir Shah; Mohsin Kazi; Muneeb U Rehman
Journal:  Diagnostics (Basel)       Date:  2021-02-10

9.  MiR-146a regulates regulatory T cells to suppress heart transplant rejection in mice.

Authors:  Jian Lu; Weiwei Wang; Peiyuan Li; Xiaodong Wang; Chao Gao; Baotong Zhang; Xuezhi Du; Yanhong Liu; Yong Yang; Feng Qi
Journal:  Cell Death Discov       Date:  2021-06-17

10.  Co-Adjuvant Therapy Efficacy of Catechin and Procyanidin B2 with Docetaxel on Hormone-Related Cancers In Vitro.

Authors:  Mª Jesús Núñez-Iglesias; Silvia Novio; Carlota García; Mª Elena Pérez-Muñuzuri; María-Carmen Martínez; José-Luis Santiago; Susana Boso; Pilar Gago; Manuel Freire-Garabal
Journal:  Int J Mol Sci       Date:  2021-07-02       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.